Blue color blindness is a problem with seeing short-wavelength (“blue”) light accurately. It happens when the S-cones (the blue-sensitive cone cells in the retina) don’t work normally or are missing. People may confuse blue with green and yellow with red, and many colors can look less bright overall. Inherited forms usually involve changes in the OPN1SW gene, which encodes the blue-cone opsin. Acquired forms can arise later in life from eye disease, lens changes, or certain medications. AAO+3National Eye Institute+3MedlinePlus+3

Blue color blindness means your eye’s short-wavelength (S-cone) system—responsible for seeing blue and distinguishing blue–yellow differences—doesn’t work normally. In congenital tritan defects, changes in the OPN1SW (S-cone opsin) pathway reduce or block S-cone signals. In acquired tritan defects, blue–yellow problems arise from other eye diseases (like cataract, macular disease, glaucoma) or certain medicines that affect the retina or optic nerve. Congenital tritan defects are rare compared with red-green types and affect both sexes. There’s no cure for congenital color vision deficiency; care focuses on safety, adaptation, testing, and treating any underlying eye disease if present. PubMed+2MDPI+2

Blue color blindness is a problem with the eye’s blue-sensing cone cells (S-cones). People have trouble telling blue from green and yellow from pink, and colors can look less bright. There are two types: tritanopia (the blue cones are missing) and tritanomaly (the blue cones work poorly). It is much less common than red–green color blindness and can be inherited or acquired later from eye disease, aging, or some medicines. There is no cure today for congenital tritan defects, but people can learn smart ways to adapt and protect their vision. nei.nih.gov+1

---

Other names

Blue color blindness is also called tritan color vision deficiency, tritanopia (complete blue-cone loss), tritanomaly (partial blue-cone function), and blue-yellow color vision deficiency. These terms all refer to reduced or absent S-cone function causing difficulty along the blue–yellow color axis. National Eye Institute

---

Types

There are two main clinical types along a spectrum:

• Tritanomaly (partial): The blue cones are present but do not work well. People mainly confuse blue vs. green and yellow vs. red, especially in pale or pastel shades. Colors can seem dull. National Eye Institute

• Tritanopia (complete): The blue cones do not function at all. Confusions are broader (for example, blue/green, purple/red, yellow/pink), and many colors look much less bright. Genetic tritan defects usually relate to OPN1SW and often follow autosomal dominant inheritance. National Eye Institute+1

Background detail: the OPN1SW gene makes the pigment in S-cones. Faults in this gene are a well-documented cause of inherited tritan defects. MedlinePlus+1

---

Causes

1. Inherited OPN1SW variants. Changes in the OPN1SW gene disrupt the blue-cone pigment, so S-cones don’t signal correctly. This is the classic cause of congenital tritanopia/tritanomaly. MedlinePlus+1

2. Age-related lens yellowing (nuclear sclerosis/cataract). As the lens becomes yellow with age or cataract, it blocks blue light, creating a blue–yellow color vision loss pattern. AAO

3. Glaucoma. Damage to retinal ganglion cells and inner retina in glaucoma commonly produces acquired blue–yellow color defects before other changes are noticed. AAO

4. Age-related macular degeneration (AMD). Macular damage impairs cone function. Acquired color loss in AMD frequently affects the blue–yellow axis first. Medical News Today

5. Diabetic retinopathy. Macular edema and retinal ischemia in diabetes degrade cone signaling and often cause a blue–yellow deficit. Medical News Today

6. Retinitis pigmentosa and cone dystrophies. Inherited retinal disorders that damage photoreceptors can produce tritan-like losses when S-cones or macula are involved. Wikipedia

7. Optic nerve disease (e.g., optic neuropathy). Damage to the optic nerve can impair color processing; acquired defects often include a blue–yellow component, especially with macular involvement. AAO

8. Retinal detachment or macular edema. Structural changes in the macula interrupt normal cone signaling, frequently manifesting as blue–yellow confusion. AAO

9. Post-surgical or lens/implant factors. Certain intraocular lenses or lens changes alter blue light transmission and can shift blue–yellow perception. AAO

10. Medication effects—cardiac glycosides (e.g., digoxin). Cardiac glycosides can cause disturbances in color perception, often described as yellowing of vision, reflecting blue–yellow pathway disruption. AAO

11. Medication effects—phosphodiesterase-5 inhibitors (e.g., sildenafil). Transient blue-tinge or color shifts are reported after dosing, reflecting short-wavelength pathway effects. AAO

12. Medication effects—antimalarials/retinotoxic drugs. Drugs with retinal toxicity risk (e.g., chloroquine/hydroxychloroquine, thioridazine) can disturb cone function and color perception, sometimes in the blue–yellow range. AAO

13. Toxic exposure (organic solvents). Industrial solvent exposure has been linked to acquired color vision loss, commonly of the blue–yellow type. AAO

14. Parkinson’s disease and some neurodegenerative disorders. Central visual processing can be affected in Parkinson’s, and blue–yellow losses are often reported. AAO

15. Traumatic eye injury. Trauma to the macula, lens, or optic nerve may reduce S-cone pathway function and cause blue–yellow confusion. AAO

16. Inflammatory macular disease (e.g., central serous chorioretinopathy). Macular fluid or inflammation disrupts cone alignment and can create a blue–yellow deficit. AAO

17. Ischemic eye disease (e.g., retinal vein occlusion). Poor blood flow injures macular cones; color errors tend to follow the blue–yellow axis early on. AAO

18. Inherited macular dystrophies other than OPN1SW defects. Some macular dystrophies reduce S-cone function secondarily, yielding a tritan-like profile. Wikipedia

19. Media opacity other than cataract (e.g., corneal scarring). Any opacity that preferentially filters blue light can bias color perception toward a blue–yellow deficit. AAO

20. Normal aging without frank disease. Even without diagnosed cataract, slow lens yellowing and neural aging can reduce blue sensitivity with time. IOVS

---

Common symptoms

1. Blue–green mix-ups. Many blues and greens look alike, so separating teal, turquoise, or aqua from green shades can be hard in daily life. National Eye Institute

2. Yellow–red confusion. Pale yellows can seem reddish or vice versa, especially in low light or with pastel colors. National Eye Institute

3. Colors look less bright. Overall color vividness drops, so objects may appear washed out. National Eye Institute

4. Trouble with purples. Purple may look more like red, because the blue component is not seen normally. National Eye Institute

5. Difficulty sorting similar light colors. Pastel sets (e.g., paints, clothes) are hard to arrange by hue along the blue–green/yellow axis. (This is exactly what arrangement tests measure.) NCBI

6. Reading color maps or charts is slow. When legends rely on blue–green or yellow–red, understanding graphs or maps becomes challenging. National Eye Institute

7. Matching clothing and design elements. Picking “matching” blues/greens or coordinating outfits that rely on these hues can be frustrating. National Eye Institute

8. Lighting sensitivity of color naming. Warm bulbs and dim conditions make blue–yellow decisions even harder. National Eye Institute

9. Mistakes with safety color codes using blue/green. Labels or wires that use these hues may be misread without redundancy. National Eye Institute

10. Dull sky or sea tones. Natural scenes with a strong blue component may look less saturated. National Eye Institute

11. Trouble telling ripe fruit by color. Yellowing or subtle shade changes (bananas, citrus) can be misleading. National Eye Institute

12. Fatigue during color-heavy tasks. Sorting colored items by shade can be tiring because the visual system works harder to use brightness or context instead of hue. NCBI

13. Frequent re-checking of labels. People rely more on text labels than color cues to avoid mistakes in daily tasks. National Eye Institute

14. Frustration with “color-only” instructions. Directions that say “choose the blue icon” or “follow the green line” can cause errors without alternate markings. National Eye Institute

15. Sometimes no obvious symptom. Mild tritanomaly can go unnoticed until formal testing or until a color-critical job/school screening. National Eye Institute

---

Diagnostic tests

A) Physical exam & clinical assessment

1. Comprehensive eye exam and history. The clinician reviews family history, past eye problems, injuries, and medications (some affect color vision), then checks basic sight. This helps separate inherited from acquired color loss. AAO

2. Visual acuity and contrast sensitivity. Measuring clarity and contrast provides context; reduced acuity or contrast points toward macular or optic nerve disease driving a tritan-like loss. AAO

3. Slit-lamp examination of the lens. The doctor looks for lens yellowing or cataract, which blocks blue light and can cause blue–yellow defects. AAO

4. Intraocular pressure (IOP) and optic nerve evaluation. These look for glaucoma, a common cause of acquired blue–yellow color loss. AAO

5. Dilated fundus exam of the macula and retina. Direct examination can reveal AMD, diabetic retinopathy, edema, or other macular disorders that often produce a tritan pattern. Medical News Today

B) Manual/psychophysical color vision tests

6. HRR (Hardy–Rand–Rittler) pseudoisochromatic plates (4th ed.). A plate test designed to screen and categorize red-green and blue–yellow (tritan) loss, grading severity and type more robustly than older plates. Widely used in clinics. Gulden Ophthalmics+2cdnimages.opentip.com+2

7. Farnsworth D-15 arrangement test. You arrange 15 colored caps in hue order. Specific confusion lines reveal tritan defects and give a sense of severity; useful for acquired losses. NCBI+1

8. Lanthony Desaturated D-15. A “softer” version that stresses the system and can unmask milder tritan errors than the standard D-15. NCBI

9. Farnsworth–Munsell 100-Hue test. A longer arrangement test across a wide range of hues, offering a detailed “error score” and axis analysis that can highlight blue–yellow deficits. NCBI

10. Anomaloscope (Moreland equation for tritan). A lab-grade device where you match a test light by mixing primaries; the Moreland setting targets blue–yellow function. It’s a classic reference method, though standardization and repeatability for tritan assessment have been debated. Wiley Online Library+2ResearchGate+2

11. Computerized color vision tests (e.g., Cone Contrast Test, CAD). Modern digital tests quantify thresholds for S-cone (blue) pathways and are increasingly used in occupational/military screening. OUP Academic

C) Laboratory & pathological investigations

12. Genetic testing for OPN1SW. When an inherited tritan defect is suspected, testing the OPN1SW gene can confirm the diagnosis and guide family counseling. MedlinePlus+1

13. Systemic work-up for acquired causes (selected labs). When disease-related color loss is suspected, clinicians may order labs guided by history (e.g., diabetes tests for suspected diabetic eye disease). The aim is identifying and treating the underlying condition. Medical News Today+1

14. Medication review/toxicity monitoring. Although not a “lab test,” systematic review of medications (e.g., digoxin, retinotoxic drugs) is a core investigative step in acquired blue–yellow loss. AAO

D) Electrodiagnostic tests

15. Full-field electroretinography (ERG). ERG measures the retina’s electrical response to light. Patterns can suggest cone pathway dysfunction; S-cone targeted ERG protocols directly probe the blue-cone pathway. Nature+1

16. S-cone ERG (ISCEV extended protocol). Specialized stimuli isolate S-cone responses and can help confirm inherited tritanopia or quantify S-cone loss in retinal disease. ResearchGate+1

17. Pattern ERG (PERG) or chromatic VEP (when available). These assess macular/optic nerve function and can support a diagnosis of acquired tritan loss tied to macular or optic nerve pathology. Nature

E) Imaging tests

18. Optical coherence tomography (OCT) of the macula. OCT shows cross-sections of the retina to detect macular edema, dystrophy, or photoreceptor layer damage that often underlies acquired tritan defects. Medical News Today

19. Fundus photography and autofluorescence. High-resolution images document macular disease and RPE changes that correlate with color vision loss patterns. Medical News Today

20. Anterior segment imaging / slit-lamp documentation. Imaging or documenting lens cataract helps explain blue-light filtering and a tritan-type deficit; it’s part of building a full picture of cause and prognosis. AAO

Non-pharmacological treatments (therapies & other supports)

1) Professional low-vision/vision-rehab training.
A low-vision specialist teaches practical strategies—labeling systems, contrast tricks, lighting control, and task-specific filters—to reduce color-mix-ups (like laundry, wiring, maps) and to meet work or driving standards. Training is personalized after formal color testing (e.g., Farnsworth D-15). NCBI

2) Task-specific tinted filters (trialed, not “cures”).
Neutral-density or selective filters may boost contrast in certain environments (screens, signage, safety labels). Evidence is mixed; some studies show gains in reaction time or test scores, others show little change, so filters should be trialed chair-side and used only when they help the task. PMC+1

3) Controlled lighting and glare management.
Bright, even, non-glare lighting and tuned screen brightness can make hue differences a little clearer and reduce fatigue. Avoid yellowing bulbs; use high-CRI LEDs and anti-glare surfaces for reading, labeling, and color-critical work. nei.nih.gov

4) Digital accessibility settings.
Use strong contrast themes, symbols + text labels (not color alone), and custom color maps on phones and PCs. Apps that replace color-only cues with text or shapes reduce errors in charts, maps, and UIs. nei.nih.gov

5) Occupational accommodations.
When jobs rely on color (labs, wiring, safety), swap color codes for shape, position, or text, or add barcode/RFID checks. Employers can satisfy safety and accessibility standards by removing color-only signals. nei.nih.gov

6) Traffic-signal strategies.
Memorize signal order, use intersection signage and lane arrows, and keep windshield and glasses clean to improve contrast. Night glare control lenses may help comfort (not color). nei.nih.gov

7) Clothing and home labeling systems.
Permanent tags (e.g., “navy blazer A,” “pants B”) and pre-matched sets remove color-matching guesswork. Use daylight-balanced bulbs in closets to reduce yellowing effects from warm light. nei.nih.gov

8) Education and family coaching.
Teachers can avoid color-only grading keys and use patterns/symbols on charts. Early support prevents frustration and helps children build strong learning habits. nei.nih.gov

9) Eye-health maintenance and systemic disease control.
Because acquired tritan loss can come from cataract, glaucoma, diabetes, or optic neuropathies, regular eye exams and good blood sugar and blood pressure control protect remaining function. surveyophthalmol.com+1

10) Medication safety review.
Ask clinicians to review drugs that can disturb color perception (for example PDE-5 inhibitors and digoxin) and to adjust when medically appropriate; this can prevent superimposed color shifts. Do not stop medicines on your own. PubMed+1

11) Formal color testing to map strengths.
Tests like Farnsworth D-15 and related arrangement tests help identify confusion lines and guide custom adaptations (filters, lighting, task setup). NCBI

12) Environment design with redundant cues.
At home/work, pair colors with text, icons, shapes, or positions (e.g., identical containers labeled in big print). This lowers daily error rates. nei.nih.gov

13) Screen/UI calibration and profile presets.
Color-managed workflows (ICC profiles) and “color-weak safe” palettes reduce ambiguous hues in design, coding, dashboards, and medical monitors. nei.nih.gov

14) Safety labeling upgrades.
Replace red/green or blue/yellow warnings with black-and-white icons + text and high-contrast borders. This is inexpensive and highly effective. nei.nih.gov

15) Use of electronic magnification/contrast tools.
e-Readers and cameras can shift hues or boost contrast on demand to make a color cue stand out (useful on maps, lab plates, plant leaves). nei.nih.gov

16) Personal color libraries / swatches under daylight bulbs.
Create a verified set of reference swatches (e.g., wardrobe colors) viewed under 5000–6500 K lighting to reduce mix-ups between, say, blue vs. green. nei.nih.gov

17) UV and blue-light protection for eye health.
UV protection helps prevent lens yellowing (cataract), which otherwise worsens blue discrimination with age; this is preventive for acquired issues. ophthalmologyscience.org

18) Counseling on career planning and licensing.
Some jobs have color-vision standards. Early counseling prevents barriers and helps candidates document reasonable accommodations where standards permit. nei.nih.gov

19) Community & school screening (not online self-tests).
Online tests are not diagnostic; screening should be done with validated charts and arrangement tests in proper lighting. Color Blind Tests+1

20) Keep expectations realistic about consumer “color-blind glasses.”
Some filters can help certain tasks in some people, but they are not cures, and results vary. Choose evidence-aware, task-specific trials. Nature+1

---

Drug treatments

There are no FDA-approved medications that restore congenital blue color vision (tritanopia or tritanomaly). Current clinical practice focuses on adapting tasks, treating acquired causes (like cataract or retinal disease), and avoiding color-distorting medicines when safe to do so. Because your request asked for “20 drug treatments from accessdata.fda.gov,” it’s important to say clearly that no such FDA-approved drugs exist for this condition. Listing drugs as “treatments” here would be inaccurate and unsafe. nei.nih.gov

What medicine can still matter?

• If a disease causes acquired tritan loss (for example, diabetic retinal disease, optic neuritis, glaucoma), standard treatments for that disease may help stabilize vision—but they do not specifically restore blue color vision. surveyophthalmol.com

• Some medicines can distort color (for example sildenafil may cause a blue tint, and digoxin may cause yellow vision)—so a clinician may adjust or switch therapy if color distortion is harmful. PubMed+1

---

Dietary molecular supplements

These nutrients support overall retinal health or macular pigment. They do not fix tritanopia, but they can support eye wellness, particularly in aging or comorbid eye disease.

1) Lutein (10–20 mg/day).
Lutein builds macular pigment, which filters blue light and offers antioxidant protection. Meta-analyses show dose-response increases in macular pigment optical density (MPOD). This supports retinal resilience but does not restore S-cones. Discuss with an eye-care professional if you have other eye disease. PubMed+1

2) Zeaxanthin (2–10 mg/day, often paired with lutein).
Zeaxanthin works with lutein in the macula; combined supplementation is part of AREDS2-style strategies for macular health (for AMD risk, not tritanopia). It can raise MPOD over months. nei.nih.gov+1

3) Omega-3 fatty acids (DHA/EPA; food or 1–2 g/day supplement if advised).
Omega-3s are key for photoreceptor membranes. Reviews suggest ocular benefits, though short-term trials show no quick ERG changes; choose a food-first approach (fatty fish) unless your clinician recommends supplements. PMC+1

4) Vitamin C (≈500 mg/day in AREDS-type formulas when indicated).
Antioxidant support for retinal tissues; included in AREDS2 mixes for AMD progression risk reduction (for the right AMD stage). Not a tritanopia treatment. nei.nih.gov

5) Vitamin E (≈400 IU/day in AREDS-type mixes when indicated).
A fat-soluble antioxidant used in AREDS-style formulas for certain AMD patients; talk to your doctor about dosing and safety. nei.nih.gov

6) Zinc (≈80 mg zinc oxide/day in AREDS-style mixes when indicated; with copper).
Zinc is part of enzyme systems in the retina; it appears in AREDS2 formulations for AMD stage-specific care. Use with copper to avoid deficiency. nei.nih.gov

7) Copper (2 mg/day in AREDS-style mixes when indicated).
Paired with high-dose zinc to prevent copper-deficiency anemia; again, this is AMD-specific, not a tritanopia treatment. nei.nih.gov

8) Diet rich in xanthophyll-foods (spinach, kale, eggs).
Food sources of lutein/zeaxanthin raise MPOD over time and are an easy, safe foundation for eye health. PMC

9) Mediterranean-style pattern.
A pattern high in leafy greens, fruit, legumes, nuts, whole grains, and fish supports long-term retinal health and reduces overall oxidative stress. nei.nih.gov

10) Avoid megadoses without indication.
Supplements can interact with health conditions (e.g., high-dose antioxidants) and are not indicated to fix color vision. Use clinician guidance. nei.nih.gov

---

Immunity booster / regenerative / stem-cell drugs

There are no approved immunity boosters, regenerative drugs, or stem-cell drugs that restore S-cone function in tritanopia. Gene therapy is the most promising future avenue, with encouraging results in other inherited retinal diseases and in red–green color-vision animal models, but it is not a clinical treatment for tritan defects right now. If future peer-reviewed trials in humans with tritan mutations show benefit and gain regulatory approval, this section will change. PubMed+2neitzvision.com+2

---

Surgeries

There is no surgery to cure congenital tritanopia. These procedures matter only when acquired blue–yellow problems come from treatable eye disease:

1) Cataract extraction (lens replacement).
A yellowing natural lens can filter blue light and worsen blue–yellow discrimination. Removing the cataract can change color appearance and may improve blue perception from the lens effect, but it does not fix S-cones if they are absent/dysfunctional. ophthalmologyscience.org

2) Glaucoma procedures (laser or surgery) for advanced disease.
If optic-nerve damage contributes to acquired dyschromatopsia, treating glaucoma is vital for preserving the remaining vision, though color discrimination may not normalize. surveyophthalmol.com

3) Retinal surgery for detachments.
Timely repair helps preserve photoreceptors; S-cone losses in detachments can cause tritan-like changes, so prompt surgery protects function but may not fully restore color vision. PMC

4) Intravitreal therapy for diabetic macular disease (not a “color surgery,” but part of retina care).
Treating the macula can stabilize vision in diabetic eye disease—important because diabetes is linked to blue–yellow losses—but it’s not a direct color-vision fix. cdn.fortunejournals.com

5) Avoid blue-blocking IOLs in people who rely on blue cues (individualized).
Certain intraocular lenses reduce blue light; this can alter color experience. Lens choice should be individualized with your surgeon. ophthalmologyscience.org

---

Preventions

1. Regular dilated eye exams to catch cataract, glaucoma, macular and optic-nerve disease early. surveyophthalmol.com

2. Control diabetes, blood pressure, and lipids to protect the retina. cdn.fortunejournals.com

3. UV-blocking eyewear outdoors to slow lens yellowing (cataract risk). ophthalmologyscience.org

4. Do not rely on color alone for safety at work/home; add text, shapes, and icons. nei.nih.gov

5. Ask about drug side effects that can change color vision (e.g., PDE-5 inhibitors, digoxin). PubMed+1

6. Healthy diet rich in leafy greens and fish (supports retinal health). nei.nih.gov

7. Avoid smoking, which harms ocular circulation. nei.nih.gov

8. Manage screen glare/lighting to reduce color confusion and fatigue. nei.nih.gov

9. Use validated vision tests (not random online tests) for decisions affecting school or work.

---

When to see a doctor

See an eye doctor soon if: (a) you notice new trouble telling colors apart, (b) colors look duller than before, (c) you see halos, glare, or blurred vision with color change, (d) you start a new medicine and color vision changes, or (e) a child struggles with color-coded school tasks. Early exams can find treatable causes (like cataract or glaucoma) or document an inherited condition for school/work accommodations. Mayo Clinic

---

What to eat and what to avoid

Eat a balanced, eye-friendly diet rich in leafy greens (spinach, kale), colorful fruits/veg, whole grains, legumes, and fish with omega-3s. These choices support general retinal and vascular health but do not fix tritanopia. Limit ultra-processed foods, sugary drinks, and excess alcohol; and do not smoke. If your clinician recommends AREDS2 for AMD risk, follow that plan; otherwise avoid high-dose supplements without a medical reason. National Eye Institute

---

FAQs

1) Is there a cure for inherited blue color blindness?
No. There is no cure yet for inherited tritan defects. Filters and accessibility tools can help with daily tasks. National Eye Institute

2) Can surgery fix tritanopia?
Not inherited tritanopia. Surgery helps only if the color problem comes from another disease (like cataract). PMC

3) Do color-blind glasses work for blue-yellow problems?
Tinted lenses may improve contrast for some tasks, but they do not restore normal color vision, and most data are for red-green deficiencies. American Academy of Ophthalmology

4) Which medicines can change color vision?
Labels report issues with PDE-5 inhibitors, voriconazole, cisplatin, and ethambutol (among others). Always tell your doctor if colors change. nceyes.org+3malacards.org+3ir.bauschhealth.com+3

5) Are vitamins a treatment for tritanopia?
No. Nutrients like lutein/zeaxanthin help in AMD progression risk but do not repair blue-cone function. National Eye Institute

6) Is tritanopia rare?
Yes. Congenital tritan defects are rare; many blue-yellow issues are acquired from eye disease. MDPI

7) What gene is involved?
OPN1SW, which encodes the S-cone (blue-sensitive) opsin. MedlinePlus

8) Can gene therapy help now?
Approved gene therapy (LUXTURNA) helps RPE65 disease, not color blindness. Research continues. Optica Publishing Group

9) How is tritanopia diagnosed?
With color tests that check the tritan axis (e.g., HRR, FM100, Cambridge, Cone Contrast, or Moreland anomaloscope), plus a full eye exam. PMC+2crsltd.com+2

10) Can cataracts cause blue-yellow problems?
Yes. Yellowed lenses cut blue light; surgery often makes colors brighter and bluer again. PMC

11) Does glaucoma affect color?
Often yes—blue-yellow loss can appear early in glaucoma. PMC

12) Are phone apps useful?
Yes. Apps can name colors or shift palettes to reduce mistakes, especially under good lighting. National Eye Institute

13) Should children be screened?
Yes—before school, so teachers can adjust materials and expectations. Mayo Clinic

14) Can diet “fix” tritanopia?
No. A healthy diet helps eye health but does not restore blue-cone function. National Eye Institute

15) What’s the main safety tip?
Replace color-only signals with labels, patterns, or positions (e.g., traffic lights), and keep good lighting. National Eye Institute

Disclaimer: Each person’s journey is unique, treatment plan, life style, food habit, hormonal condition, immune system, chronic disease condition, geological location, weather and previous medical  history is also unique. So always seek the best advice from a qualified medical professional or health care provider before trying any treatments to ensure to find out the best plan for you. This guide is for general information and educational purposes only. Regular check-ups and awareness can help to manage and prevent complications associated with these diseases conditions. If you or someone are suffering from this disease condition bookmark this website or share with someone who might find it useful! Boost your knowledge and stay ahead in your health journey. We always try to ensure that the content is regularly updated to reflect the latest medical research and treatment options. Thank you for giving your valuable time to read the article.

The article is written by Team RxHarun and reviewed by the Rx Editorial Board Members

Last Updated: October 29, 2025.